We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Blood-Based MCED Test Enables Early-Stage Detection for Multiple Cancer Types

By LabMedica International staff writers
Posted on 09 Jun 2025

Around 84,000 new cancer cases in the United States each year are thought to arise from obesity, and over the past two decades, the rate of obesity-related cancers has climbed markedly. More...

Thirteen malignancies linked to excess body weight now account for roughly 40% of U.S. cancer diagnoses, yet most, such as pancreatic, hepatic, and endometrial cancers, lack population-wide screening programs. New clinical evidence now shows the robust performance of a blood-based multi-cancer early-detection (MCED) assay across several high-incidence, high-mortality tumor types, including those that disproportionately affect people with obesity.

The reflex MCED blood test developed by Harbinger Health (Cambridge, MA, USA) uses specific proprietary methylation signatures in circulating tumor DNA (ctDNA) to detect the presence of cancer. The company’s technology platform integrates biological insights into cancer initiation with artificial-intelligence methods and analytical advances to deliver novel screening and diagnostic products for multiple settings and indications. The reflex workflow employs two tiers: an initial methylome-profiling assay tuned for high sensitivity to “rule out” disease, followed by a confirmatory test that uses an expanded methylation panel to enhance positive predictive value (PPV), “rule in” cancer, and pinpoint the tissue of origin (TOO).

A multicenter, case-control study designed to validate and refine Harbinger’s platform enrolled about 8,095 participants at 126 U.S. sites. The cancer arm included treatment-naïve patients with confirmed diagnoses spanning more than 20 solid and hematologic tumors, while the control arm comprised individuals with no clinical suspicion of cancer at enrollment; control participants were monitored for a year to verify their cancer-free status. The analysis cohort evaluated here consisted of 762 adults with obesity (mean age 57.1 ± 13.4 years; 63.3% female; 22.4% Black or African American; 67.8% White). Tumor types represented were breast, uterine, lung, lymphoid lineage, prostate, colorectal, pancreatic, upper gastrointestinal (esophageal, esophagogastric junction, and gastric), head and neck, liver, biliary tract, and others.

With specificity set at 98.3%, the reflex assay demonstrated conventional sensitivities of 25.8% for early-stage (I–II) cancers and 80.3% for late-stage (III–IV) cancers. Using the same specificity, the test achieved a 50.9% conventional sensitivity for malignancies lacking established U.S. screening programs. Among cases that generated a tissue-of-origin readout, the overall accuracy of the TOO assignment was 36%. Tumor-specific PPVs for the TOO call were 15% for hepatobiliary, 22% for upper GI, 33% for colorectal, and 25% for lung cancers.

“The results from our study demonstrate the robust early-stage performance of our test across multiple cancer types,” said Hutan Ashrafian, M.D., Ph.D., M.B.A., Chief Medical Officer of Harbinger Health. “While the obesity-associated subset demonstrates our ability to target high-risk groups, the broader results underscore the platform’s potential across a wide range of deadly cancers that lack mechanisms for effective, large-scale early detection via routine screening.”

Related Links:
Harbinger Health


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
STI Test
REALQUALITY RQ-SevenSTI
New
Glucose Tolerance Test
NERL Trutol
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Microbiology

view channel
Image: The U.S. FDA-cleared IntelliSep rapid host response diagnostic represents a breakthrough in sepsis care (Photo courtesy of Cytovale)

Rapid Diagnostic Test Slashes Sepsis Mortality by 39%

Sepsis remains one of the most challenging and fatal conditions in contemporary healthcare, accounting for nearly one-third of all hospital-related deaths in the United States. In emergency departments... Read more

Industry

view channel
Image: The knowledge transfer partnership will further develop technology to rapidly diagnose serious and high-risk infectious diseases (Photo courtesy of Aston University)

Aston University and BG Research Partner to Commercialize Groundbreaking Medical Diagnostic

Technology that can rapidly diagnose high-consequence infectious diseases will take a major step forward towards commercialization, thanks to a new partnership. A Knowledge Transfer Partnership (KTP)... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.